Here you will find media publications about us and contact information for press inquiries.
All
Interviews
Expertise
Mentions
«Andrey Glukhov told Forbes how the holding company restructured its logistics in response to the fuel shortage.»
«AppScience is strengthening its pharmaceutical division by developing the first Russian generic of vortioxetine.»
«Concentration is launching low-volume chemical production in the Tula Region with a RUB 350 million investment.»
«Concentration is investing in the launch of a production facility for the synthesis of chemical feedstocks and the manufacture of intermediates.»
«The founders told "Founders" magazine why the next ten years of the chemical market are about import localization, consolidation, and digitalization.»
«Ilyas Arifulin, Head of the Pharmaceutical Company, on why classifieds serve as an entry point for finding buyers — but not as a turnkey transaction tool.»
«Andrey Glukhov, Chief Operating Officer, on why the retraining initiatives of Anthropic and OpenAI are redundant.»
«Andrey Glukhov's column: how the company switched Middle Eastern supply routes to other jurisdictions in under a week — and what impact that had.»
«Andrey Glukhov on why there is so much uncertainty in international logistics — and where AI delivers tangible cost savings.»
«Marsel Gumerov and Igor Yaremenko on the Forbes podcast "Something Went Wrong" — about the lessons learned from rapid growth and why focus matters more than pace.»
«Andrey Glukhov assessed the volume of pharmaceutical imports from and through Iran, and outlined the main barriers: indirect payment channels, slow logistics, and regulatory constraints.»
«Igor Yaremenko, co-founder of AppScience, commented to Forbes on the role of private investment in the development of knowledge-intensive industries.»
«Ilyas Arifulin, Head of the Pharmaceutical Company, on why the share of bioequivalence studies in Russia has grown significantly — and what that means for competition among CROs.»
«Igor Yaremenko outlined the funding stages of AppScience — from the founders' own capital to external investors.»
«AppScience is developing a Russian generic of vortioxetine with a planned market launch by 2027.»
«AppScience is strengthening its pharmaceutical division by developing the first Russian generic of vortioxetine.»
«Alexander Panov on the raw material margins of semaglutide generics — and why the active substance costs less than the injection pen.»
«Alexander Panov on generic quality, the volume of grey imports in pharmaceuticals — and why half of a drug's quality is determined by its raw materials.»
«Vedomosti reviewed six years of the company's journey — from express reagent delivery during the pandemic to a strategy of building a fine chemicals industry and a vertically integrated chemical holding.»
«Igor Yaremenko, Marsel Gumerov, and Maxim Pustovalov — on how chemistry faculty classmates turned scientific expertise into a business — and why they moved from distribution into manufacturing.»
«A column by Marsel Gumerov: why fine chemistry cannot be fully import-substituted.»
«Maxim Pustovalov on the real structure of pharmaceutical raw material supply chains — and why the direct route is almost never the actual route.»
«AppScience founders made it onto the Forbes 30 Under 30 list for launching a service that accelerated the delivery of rare chemical reagents to Russian laboratories and pharmaceutical companies.»
«Igor Yaremenko on the first restructuring of pharmaceutical supply chains after February 2022 — and how to deliver critical medicines when previous routes were shut down.»
«Marsel Gumerov is mentioned as a co-founder of AppScience and one of the creators of the startup focused on the rapid delivery of rare reagents.»
«Co-founder Igor Yaremenko on why Russia's reagent market is import-dependent — and what that means for research timelines.»
«Maxim Pustovalov and Igor Yaremenko on the podcast "Business Management" — about how urgent reagent delivery works, and on partnership, competition, and risks.»
«Three graduates of Moscow State University's Chemistry Faculty cut the wait time for rare reagents from months to two or three weeks — and reached a monthly revenue of RUB 50 million.»
Your request has been submitted. We will get back to you shortly.
